A central line infection lawsuit is a legal claim seeking compensation for infections that develop after a central line catheter—a tube placed near the heart to deliver medication or draw blood—becomes contaminated or fails to prevent bacterial growth. These lawsuits typically target the device manufacturer or the healthcare facility responsible for implanting or maintaining the catheter. The most prominent litigation involves Bard’s PowerPort catheter, with over 3,384 cases consolidated in a multi-district litigation (MDL 3081) in Arizona as of May 2026, many alleging serious infections that required hospitalization, additional procedures, or caused permanent harm.
Central line-associated bloodstream infections, medically known as CLABSI, are among the most serious hospital-acquired complications. When germs enter a central line, they can spread rapidly through the bloodstream, causing sepsis, organ damage, or death. Unlike routine infections that can be treated with antibiotics, CLABSI cases often involve expensive emergency care, prolonged hospitalization, and long-term health consequences. Patients harmed by defective catheters or improper insertion techniques have increasingly turned to litigation to recover medical costs and damages—and the legal system has responded by organizing thousands of cases into coordinated proceedings where key facts can be tested in bellwether trials before judges and juries.
Table of Contents
- What Are Central Line Infections and Why Do They Lead to Lawsuits?
- The Bard PowerPort MDL—What You Need to Know About the Major Litigation
- Settlement Amounts and Compensation in Central Line Infection Cases
- How to File a Claim and the Legal Process
- The Broader Impact—CLABSI Statistics and Hospital Accountability
- What Bellwether Trials Mean for Your Case
- Hospital Accountability and the Future of Central Line Litigation
- Conclusion
What Are Central Line Infections and Why Do They Lead to Lawsuits?
A central line is a medical catheter inserted into a large vein, typically in the chest, neck, or arm, to allow direct access to the bloodstream. These devices are essential for patients requiring long-term medication delivery, chemotherapy, nutrition support, or frequent blood draws. However, central lines also create a potential pathway for bacteria to enter the bloodstream. Central line-associated bloodstream infections (CLABSI) occur when microorganisms colonize the catheter, the insertion site, or the surrounding tissue and migrate into the blood.
Lawsuits arise when patients claim the infection was caused by a defective device design, a manufacturing defect, inadequate warnings about proper insertion or maintenance, or healthcare provider negligence. In the PowerPort litigation, plaintiffs allege that the catheter’s design allows bacterial biofilm to form more easily than competing devices, or that the device failed structurally, allowing infection pathways. The distinction matters: a poorly designed device can be recalled and replaced for millions of patients, whereas a negligence claim typically involves a single healthcare facility. When a device manufacturer faces thousands of claims, consolidation into an MDL allows for more efficient handling and encourages settlement negotiations that might not occur in individual cases spread across different courts.
The Bard PowerPort MDL—What You Need to Know About the Major Litigation
The Bard PowerPort litigation represents the largest coordinated central line infection lawsuit in recent years. As of May 2026, 3,384 cases were consolidated in MDL 3081 in the U.S. District Court for the District of Arizona. The Judicial Panel on Multidistrict Litigation consolidated the cases to streamline discovery, reduce duplicative litigation, and allow bellwether trials—test cases where juries or judges decide a representative claim—to establish settlement benchmarks for the broader group. The first bellwether trial involved plaintiff Robert Cook, originally scheduled for April 21, 2026, addressing central line catheter infection claims.
A second bellwether trial was scheduled for plaintiff Wanda Miller on July 7, 2026, but Miller died on February 2, 2026, before trial. Additional bellwether trials are scheduled for May Lattanzio and Lloyd Sorensen, both alleging infection-related injuries. The outcomes of these trials will likely influence settlement negotiations for the remaining cases. A crucial limitation to understand: even a plaintiff victory at trial does not automatically entitle all other claimants to similar awards. Each case depends on its specific facts, medical records, and damages, though favorable verdicts do create pressure on defendants to settle rather than face similar jury decisions repeatedly.
Settlement Amounts and Compensation in Central Line Infection Cases
Settlement ranges in the PowerPort litigation vary significantly based on injury severity. For infection-only cases—where the plaintiff developed CLABSI but recovered or managed the infection without catastrophic injury—settlements are typically estimated at $30,000 to $100,000. This range reflects medical costs, pain and suffering, and time lost to treatment, but excludes claims of permanent organ damage or significantly shortened lifespan.
Cases involving catheter fracture combined with organ damage command substantially higher settlement valuations, ranging from $175,000 to $350,000. For example, a patient whose PowerPort fractured, dispersing fragments into the bloodstream and causing sepsis with permanent kidney or heart damage, could expect compensation approaching the higher end of that range. However, these figures are estimates based on defense counsel analysis and prior MDL settlements—actual awards depend on jury verdict, settlement negotiation, and the specific damages proven in each case. Plaintiffs should be cautious about assuming their case will fit neatly into a published range; cases involving exceptional medical negligence, age of the plaintiff, or unusual complications may settle for more or less.
How to File a Claim and the Legal Process
If you believe you developed a CLABSI related to a defective central line catheter, the first step is to gather medical records documenting the catheter brand, insertion date, infection diagnosis, and subsequent treatment. Most cases join existing MDL proceedings rather than being filed individually, which means consulting with an attorney experienced in device litigation is essential—they can evaluate whether your case qualifies for inclusion and advise on timing, which is critical because statutes of limitations vary by state. Once a claim is filed in the MDL, it enters the discovery phase, where both sides exchange documents, medical records, and expert reports.
Plaintiffs typically retain medical and engineering experts to establish that the device was defective or that proper warnings were missing. Defense counsel will argue the infection resulted from user error, insertion technique failure, improper maintenance, or an unavoidable complication inherent to central line use. If bellwether trials occur, your case may not be selected, but the outcomes will likely influence settlement offers. The trade-off of MDL participation is efficiency—coordinated management reduces costs and speeds resolution—but you may have less individual control over settlement strategy compared to a solo lawsuit.
The Broader Impact—CLABSI Statistics and Hospital Accountability
The scope of central line infection harm extends well beyond the PowerPort litigation. According to U.S. healthcare data, approximately 4,500 CLABSI cases were reported in 2020, representing a striking 53% increase from the previous year. The average cost to treat a single CLABSI case is approximately $46,000, a figure that includes hospitalization, antimicrobial therapy, additional procedures, and potential long-term care. These statistics understate the human cost: many CLABSI patients experience organ failure, permanent disability, or death.
In response to persistently high CLABSI rates, the Centers for Medicare & Medicaid Services (CMS) has implemented penalty mechanisms. In 2025, 724 hospitals received payment reductions based on composite quality scores that include CLABSI performance. This accountability measure incentivizes hospitals to improve insertion practices, staff training, and ongoing catheter care protocols. However, a critical warning: the existence of CMS penalties does not prevent future infections. Hospitals vary widely in their compliance and resource commitment, and patients in under-resourced facilities may face higher risks. Individual accountability through lawsuits remains an important supplement to regulatory penalties.
What Bellwether Trials Mean for Your Case
Bellwether trials are tests of liability and damages that occur before a broader population of claims settles or goes to trial. In the PowerPort MDL, these trials serve several functions: they allow both sides to present their strongest arguments, they provide evidence of jury attitudes toward the claims and defendant arguments, and they generate concrete damage awards that influence settlement negotiations. For claimants, a favorable bellwether verdict can strengthen their negotiating position and suggest that settling will be less expensive for the defendant than continued litigation. The April 2026 Robert Cook bellwether trial examined whether the PowerPort catheter’s design contributed to infection development.
The subsequent trials involving Lattanzio and Sorensen will test similar claims. One important caveat: a plaintiff loss in a bellwether trial can also influence settlement dynamics—downward. If juries consistently reject plaintiff claims, defendants may lower their settlement offers. Therefore, bellwether outcomes are double-edged; they reduce uncertainty but do not guarantee favorable settlements for all claimants.
Hospital Accountability and the Future of Central Line Litigation
The litigation landscape for central line infections reflects a broader tension in healthcare: while infection prevention has improved through standardized protocols and staff training, device defects and human error continue to cause preventable harm. The FDA maintains authority to issue recalls or warnings for defective catheters, but litigation has historically forced manufacturers to correct problems faster than regulatory processes alone. The PowerPort MDL demonstrates how coordinated litigation can pressure a device manufacturer into settlement negotiations that might resolve thousands of claims more efficiently than individual trials.
Looking ahead, central line infection claims will likely continue as long as catheters are implanted and infections occur. The outcome of current bellwether trials in the PowerPort MDL may influence device design standards industry-wide, prompt hospitals to invest more heavily in CLABSI prevention, and establish precedent for settlement valuations in future catheter-related litigation. Patients and their families should remain vigilant about monitoring central line care and recognizing signs of infection—fever, redness at the insertion site, or unexplained illness during catheter use—as early detection and treatment can prevent catastrophic outcomes.
Conclusion
Central line infection lawsuits address one of the most serious complications in modern healthcare: infections that develop when catheters placed near the heart become contaminated. The Bard PowerPort MDL, with 3,384 consolidated cases as of May 2026, represents the most significant coordinated litigation on this issue, with settlement ranges of $30,000 to $100,000 for infection-only cases and $175,000 to $350,000 for cases involving severe organ damage. Bellwether trials like those of Robert Cook and others will establish damage benchmarks and test liability theories that influence settlement negotiations.
If you believe you developed a central line infection caused by a defective catheter or improper medical care, consult with an attorney experienced in product liability and MDL litigation as soon as possible. Time is critical because statutes of limitations apply, and medical records documenting the device brand, insertion date, and infection timeline are essential to supporting your claim. The broader context of 4,500 annual CLABSI cases, $46,000 average treatment costs, and CMS penalties on 724 hospitals underscores that this is not a rare problem—it is a systemic issue where both regulatory oversight and litigation serve important roles in holding manufacturers and healthcare facilities accountable.